Lacosamide Oral Solution
NDC Package 73190-103-20

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Lacosamide Oral Solution (lacosamide) solution is lacosamide is used to prevent and control seizures. This formulation utilizes a solution delivery system. Marketed by Avkare, this product is identified by NDC 73190-103 and is authorized under FDA application ANDA219699.

Identification & Billing

NDC Package Code
73190-103-20
Package Description
200 mL in 1 BOTTLE
Product Code
73190-103
11-Digit Billing Format
73190010320

Clinical Specifications

Proprietary Name
Lacosamide Oral Solution
Non-Proprietary Name
Lacosamide
Substance Name
Lacosamide
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
LACOSAMIDE 10 mg/mL
Pharmacologic Class
Decreased Central Nervous System Disorganized Electrical Activity - [PE] (Physiologic Effect)
Usage Information
Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.
DEA Schedule
Schedule V (CV) Substances

Regulatory & Marketing

Labeler Name
Avkare
Product Type
Human Prescription Drug
FDA Application #
ANDA219699
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-09-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73190-103-20 identifies a specific commercial package of 200 ml in 1 bottle of Lacosamide Oral Solution, a human prescription drug labeled by Avkare. This solution is formulated for oral use and contains lacosamide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Avkare on September 09, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

How is this Avkare product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73190010320. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73190-103-20
11-Digit CMS (5-4-2)
73190-0103-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.